Your Article Summary
See Latest ArticlesA phase I/II trial of fixed-dose docetaxel plus irinotecan and escalating doses of estramustine phosphate for second-line or greater treatment of selected advanced solid tumors
Anti-Cancer Drugs, 07/02/09
Baz W et al. - In a study to evaluate the safety and efficacy of combination irinotecan, docetaxel, and estramustine for selected advanced solid tumors, it was concluded that estramustine in combination with docetaxel and irinotecan is a well-tolerated regimen with minimal hematologic toxicity, mild to moderate nonhematologic toxicity, and promising initial antitumor activity in previously treated pts with advanced solid tumors.
Methods- 22 pts were enrolled.
- The regimen consisted of docetaxel 30 mg/m2 and irinotecan 60 mg/m2 both given intravenously on days 1 and 8 every 21 days in combination with escalating doses of estramustine (500 mg/m2/day escalated to 750 mg/m2/day on days 0, 1, 2, 7, 8, and 9 given every 21 days) during phase I.
- Dose escalation was continued until maximum planned dose level of estramustine (750 mg/m2/day) was reached.
- After the appropriate phase II dose of estramustine was found, additional pts were enrolled.
- 21 of 22 pts were evaluable for toxicity and 17 for tumor response.
- Recommended phase II dose of estramustine was 750 mg/m2/day orally on days 0, 1, 2, 7, 8, and 9 given every 21 days.
- Hematologic toxicity was fairly mild, with only 1 episode of grade 3 neutropenia.
- Diarrhea was the most common nonhematologic toxicity with grade 3 toxicity occurring in 5 of 21 pts.
- Only 1 episode of venous thrombosis was observed.
- Objective response rate was 15.8%, overall clinical benefit rate was 63%, and median time to progression was 15 wks.
Related Articles
Electrocardiographic Characterization of the QTc Interval in Patients with Advanced Solid Tumors: Pharmacokinetic- Pharmacodynamic Evaluation of Sunitinib
Clinical Cancer Research, 11/16/09
Relevance Score: 80%
A dose-finding and pharmacodynamic study of bortezomib in combination with weekly paclitaxel in patients with advanced solid tumors
Cancer Chemotherapy and Pharmacology, 10/01/09
Relevance Score: 80%
Phase I Dose-Escalation and Pharmacokinetic Study of Dasatinib in Patients with Advanced Solid Tumors
Clinical Cancer Research, 10/01/09
Relevance Score: 80%
Effective strategies for management of hypertension after vascular endothelial growth factor signaling inhibition therapy: Results from a phase II randomized, factorial, double-blind study of cediranib in patients with advanced solid tumors
Journal of Clinical Oncology, 11/13/09
Relevance Score: 79%
A Phase I Dose-Escalation Study of Danusertib (PHA-739358) Administered as a 24-Hour Infusion with and without Granulocyte Colony-Stimulating Factor in a 14-Day Cycle in Patients with Advanced Solid Tumors
Clinical Cancer Research, 10/15/09
Relevance Score: 79%
Today in Pharmacology/Therapy...keeping you current
Receive free subspecialty "5-minute updates" via email
Definitive chemoradiation therapy with capecitabine in locally advanced pancreatic cancer
Anti-Cancer Drugs, 12/08/09
Is gemcitabine an option in BCG-refractory nonmuscle-invasive bladder cancer? A single-arm prospective trial
Anti-Cancer Drugs, 12/08/09
Impact of dexamethasone responsiveness on long term outcome in patients with newly diagnosed multiple myeloma
British Journal of Haematology, 12/08/09